Head of Hong Kong’s new drug regulator pledges to build trust, push innovation
Li Zili, controller of Centre for Medical Products Regulation, says body will use strategic edge to assess and bring Chinese drugs to the world
The head of Hong Kong’s new drug regulatory body has pledged to build a fully capable and globally trusted agency that will become a catalyst for medical innovation rather than merely acting as a “miniature version” of existing overseas models.
Dr Li Zili, controller of the Hong Kong Centre for Medical Products Regulation (CMPR), said that while many other places in Asia, such as mainland China, Singapore and Japan, had established regulatory agencies long ago, Hong Kong had a distinctive competitive edge.
“We are not going to be a mini-FDA, nor a miniature version of any regulatory body in the world,” he said, referring to the United States Food and Drug Administration.
Li said Hong Kong had two competitive advantages: the “one country, two systems” governing principle and the strong pharmaceutical industry on the mainland.
